Absolute Lymphocyte Count at Day 29 of Treatment Is a Powerful Predictor of Outcome in Multiple Myeloma

Narwani, Vishal; Gabriel, Joseph; Boyd, Kevin; Chevassut, Timothy

doi:10.1016/j.clml.2014.10.002

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report did not find a correlation with ALC recovery (a surrogate for immune recovery) and PFS or OS, unlike previous studies. 3,4,8 This may be a result of the higher ALCs infused in the stem cell products in this study when compared with other studies. Other factors that may account for this difference were found in previous reports that included a greater proportion of patients with refractory disease, more patients receiving bone marrow grafts (20% vs 0%), and induction regimens without IMiDs and proteasome inhibitors and no plerixafor use.…”

Section: Discussionmentioning

confidence: 71%

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Ho¹,

McCarthy²,

Wallace

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 71%

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Ho¹,

McCarthy²,

Wallace

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

“…A retrospective analysis of 537 patients with MM demonstrated that an ALC > 1.4 × 10 9 /L at diagnosis was associated with better OS [20]. After induction therapy, patients with an ALC > 0.8 × 10 9 /L also had longer OS [21]. Additionally, early recovery of ALC after ASCT is an independent prognostic factor for OS [22].…”

Section: Discussionmentioning

confidence: 99%

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma

Cho

Jo²,

Lee³

et al. 2023

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for predicting survival outcomes of patients treated with daratumumab. Methods: Between 2018 and 2021, the medical records of patients with relapsed/refractory MM (RRMM) treated with daratumumab monotherapy at 10 centers in South Korea were reviewed. We collected the ALC data at pre-infusion (D0), day 2 after the first infusion (D2), and prior to the third cycle of daratumumab therapy (D56). Results: Fifty patients who were administered at least two cycles of daratumumab were included. Overall response rate was 54.0% after two cycles of daratumumab treatment. On D2, almost all patients experienced a marked reduction in ALC. However, an increase in ALC on D56 (ALC D56 ) was observed in patients with non-progressive disease, whereas failure of ALC recovery was noted in those with progressive disease. Patients with ALC D56 > 700/μL (n = 39, 78.0%) had prolonged progression-free survival (PFS) and overall survival (OS) than those with ALC D56 ≤ 700/μL (median PFS: 5.8 months vs. 2.6 months, p = 0.025; median OS: 24.1 months vs. 6.1 months, p = 0.004). In addition, ALC D56 >700/μL was a significant favorable prognostic factor for PFS (hazard ratio [HR], 0.22; p = 0.003) and OS (HR, 0.23; p = 0.012). Conclusions: Increase in ALC during daratumumab treatment was significantly associated with prolonged survival outcomes in patients with RRMM. The ALC value can predict clinical outcomes in patients treated with daratumumab.

show abstract

“…A retrospective study conducted in 537 newly diagnosed MM patients in the Mayo Clinic indicated that the survival of MM patients with an ALC > 1.4 × 10 9 /L was associated with better overall survival (OS) (65 vs. 26 months) (2). Another study revealed the same results, in which, after induction therapy day (D) 29, 38 MM patients with an ALC > 0.8 × 10 9 /L had better OS (58.3 vs. 42.5 months) (3). Patients with ALC ≥ 1400 cells/µL or <1400 cells/µL at post-autologous stem cell transplant at D0, D15, and D90 experienced a different OS (111, 90.7, and 84 months vs. 74, 70.5, and 65 months, respectively) (4).…”

Section: Cellular Immune Profiling To Predict MM Prognosis Absolute Lymphocyte Count (Alc)mentioning

confidence: 90%

“…Another study revealed the same results, in which, after induction therapy day (D) 29, 38 MM patients with an ALC > 0.8 × 10 9 /L had better OS (58.3 vs . 42.5 months) ( 3 ). Patients with ALC ≥ 1400 cells/µL or <1400 cells/µL at post-autologous stem cell transplant at D0, D15, and D90 experienced a different OS (111, 90.7, and 84 months vs .…”

Section: Cellular Immune Profiling To Predict MM Prognosismentioning

confidence: 99%

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients

Liu

2021

Front. Immunol.

View full text Add to dashboard Cite

Despite new efficacy drugs and cell therapy have been used for multiple myeloma (MM) patients, some patients will relapse over time. We wonder the immune system play a vital role as well as MM cell during the development of disease. It is clear that the characteristic of myeloma cell is associated with the survival of MM patients. However, the link between the immune profiling and the prognosis of the disease is still not entirely clear. As more study focus on the role of immunity on multiple myeloma pathogenesis. There are plenty of study about the predictive role of immunity on the survival of multiple myeloma patients. Up to mow, the majority reviews published have focused on the immunotherapy and immune pathogenesis. It is indispensable to overlook the predictive role of immunity on multiple myeloma patients. Here, we give a review of vital previous works and recent progress related to the predictive role of immune profiling on multiple myeloma, such as absolute lymphocyte count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocytes and cytokines.

show abstract

Absolute Lymphocyte Count at Day 29 of Treatment Is a Powerful Predictor of Outcome in Multiple Myeloma

Cited by 4 publications

References 24 publications

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients

Contact Info

Product

Resources

About